10 results on '"Stephen H. Petersdorf"'
Search Results
2. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- Author
-
Roland B. Walter, Megan Othus, Bob Löwenberg, Gert J. Ossenkoppele, Stephen H. Petersdorf, Thomas Pabst, Marie-Christiane Vekemans, Frederick R. Appelbaum, Harry P. Erba, and Elihu H. Estey
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2015
- Full Text
- View/download PDF
3. Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia
- Author
-
Ram N. Ganapathi, Cheryl L. Willman, Frederick R. Appelbaum, Jerald P. Radich, John E. Godwin, Eric R. Koegle, Shannon McDonough, Megan Othus, Stephen H. Petersdorf, Anjali S. Advani, Mahrukh K. Ganapathi, Andrew P. Michelson, and Alan F. List
- Subjects
Male ,lcsh:Medicine ,Cohort Studies ,0302 clinical medicine ,Immunophenotyping ,Topoisomerase II Inhibitors ,Poly-ADP-Ribose Binding Proteins ,lcsh:Science ,Cancer ,Aged, 80 and over ,0303 health sciences ,Multidisciplinary ,biology ,Cytarabine ,Middle Aged ,3. Good health ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,Cell biology ,Anthracycline ,Daunorubicin ,CD14 ,Antineoplastic Agents ,Article ,Young Adult ,03 medical and health sciences ,Myelogenous ,Antigens, CD ,medicine ,Humans ,RNA, Messenger ,Aged ,030304 developmental biology ,business.industry ,Topoisomerase ,lcsh:R ,Adult Acute Myeloid Leukemia ,medicine.disease ,DNA Topoisomerases, Type II ,biology.protein ,Cancer research ,lcsh:Q ,business - Abstract
Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II α and topo IIβ. In 230 patients with non-M3 AML who received frontline ara-C/daunorubicin we determined expression of topo IIα and topo IIβ by RT-PCR and its relationship to immunophenotype (IP) and outcomes. Treatment outcomes were analyzed by logistic or Cox regression. In 211 patients, available for analysis, topo IIα expression was significantly lower than topo IIβ (P
- Published
- 2020
4. Effect of Measurable ('Minimal') Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
- Author
-
Derek L. Stirewalt, Elihu H. Estey, Brent L. Wood, Megan Othus, Harry P. Erba, Roland B. Walter, Frederick R. Appelbaum, and Stephen H. Petersdorf
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Myeloid ,Neoplasm, Residual ,Article ,03 medical and health sciences ,0302 clinical medicine ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Survival analysis ,Hematology ,business.industry ,Adult Acute Myeloid Leukemia ,medicine.disease ,Minimal residual disease ,Survival Analysis ,3. Good health ,Lymphoma ,body regions ,Leukemia ,Haematopoiesis ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Immunology ,business ,030215 immunology - Abstract
Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia
- Published
- 2016
5. Prognostic Significance of NPM1 Mutations in the Absence of FLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report
- Author
-
Fabiana Ostronoff, Min Fang, Jerald P. Radich, Soheil Meshinchi, Stephen H. Petersdorf, Michelle Lazenby, Alan F. List, Alan Kenneth Burnett, Elihu H. Estey, Cheryl L. Willman, Anna Evans, Era L. Pogosova-Agadjanyan, John E. Godwin, Frederick R. Appelbaum, Kenneth J. Kopecky, Vivian G. Oehler, Megan Othus, Derek L. Stirewalt, and Amanda F. Gilkes
- Subjects
Male ,FLT3 Internal Tandem Duplication ,Cancer Research ,NPM1 ,Multivariate analysis ,Genotype ,MEDLINE ,medicine ,Humans ,Survival analysis ,Aged ,Clinical Trials as Topic ,business.industry ,Age Factors ,Nuclear Proteins ,Myeloid leukemia ,ORIGINAL REPORTS ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,United Kingdom ,United States ,Leukemia ,Treatment Outcome ,fms-Like Tyrosine Kinase 3 ,Oncology ,Leukemia, Myeloid ,Tandem Repeat Sequences ,Acute Disease ,Multivariate Analysis ,Mutation ,Cancer research ,Female ,Erratum ,business ,Nucleophosmin - Abstract
Purpose Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3–internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD–negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD–negative status in older patients with AML. Patients and Methods Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Gorup (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG trials. Validation analyses then examined 1,258 patients treated in MRC/NCRI trials. Univariable and multivariable analyses were used to determine the impact of age on the prognostic significance of NPM1 mutations, FLT3-ITDs, and the NPM1-positive/FLT3-ITD–negative genotype. Results Patients with AML age 55 to 65 years with NPM1-positive/FLT3-ITD–negative genotype treated in SWOG trials had a significantly improved 2-year overall survival (OS) as compared with those without this genotype (70% v 32%; P < .001). Moreover, patients age 55 to 65 years with NPM1-positive/FLT3-ITD–negative genotype had a significantly improved 2-year OS as compared with those age > 65 years with this genotype (70% v 27%; P < .001); any potential survival benefit of this genotype in patients age > 65 years was marginal (27% v 16%; P = .33). In multivariable analysis, NPM1-positive/FLT3-ITD–negative genotype remained independently associated with an improved OS in patients age 55 to 65 years (P = .002) but not in those age > 65 years (P = .82). These results were confirmed in validation analyses examining the NCRI/MRC patients. Conclusion NPM1-positive/FLT3-ITD–negative genotype remains a relatively favorable prognostic factor for patients with AML age 55 to 65 years but not in those age > 65 years.
- Published
- 2015
6. Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy
- Author
-
Marilyn L. Slovak, Martin S. Tallman, Joseph M. Brandwein, Patrick J. Stiff, Roland B. Walter, Frederick R. Appelbaum, Kenneth J. Kopecky, Thomas J. Nevill, Megan Othus, Richard A. Larson, Leif Stenke, Harry P. Erba, and Stephen H. Petersdorf
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,Human leukocyte antigen ,Disease-Free Survival ,Article ,Internal medicine ,medicine ,Humans ,Induction failure ,Survival rate ,Preparative Regimen ,Transplantation ,Acute myeloid leukemia ,Hematopoietic cell transplantation ,business.industry ,Histocompatibility Testing ,Hematopoietic Stem Cell Transplantation ,Myeloid leukemia ,Induction chemotherapy ,Induction Chemotherapy ,Hematology ,Middle Aged ,Allografts ,3. Good health ,Survival Rate ,Leukemia, Myeloid, Acute ,Cohort ,Immunology ,Female ,business - Abstract
The aim of this study was to describe the fate of patients with newly diagnosed acute myeloid leukemia (AML) who did not achieve an initial remission while being treated on a contemporary cooperative group trial. We analyzed the outcome of patients entered into S0106, a recently reported cooperative group trial for patients with newly diagnosed AML. A total of 589 eligible patients was treated, of whom 150 (25%) did not achieve a remission while on study and were available for further analysis. The 4-year survival rate for the entire cohort of 150 patients was 23%. Among the 64 patients who received an allogeneic hematopoietic cell transplant, the 4-year survival rate was 48% compared with 4% for the 86 patients who did not undergo transplantation. Among those transplanted, we could not detect a difference in outcome according to remission status, donor source, type of preparative regimen, or cytogenetic risk category. More than 20% of patients with newly diagnosed AML who fail induction therapy can still be cured, particularly if they are able to receive an allogeneic hematopoietic cell transplant. These results suggest that early HLA typing and donor identification are important components of the initial therapy of AML.
- Published
- 2015
7. Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI
- Author
-
Elihu H. Estey, Megan Othus, Nigel H. Russell, Bob Löwenberg, Alan Kenneth Burnett, Frederick R. Appelbaum, Sucha Nand, Wim H. van der Putten, Stephen H. Petersdorf, Harry P. Erba, Robert Kerrin Hills, and Hematology
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Adolescent ,Disease-Free Survival ,Food and drug administration ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Overall survival ,Humans ,Online Only Articles ,Aged ,Aged, 80 and over ,business.industry ,Surrogate endpoint ,Event free survival ,Myeloid leukemia ,Hematology ,Middle Aged ,Survival Rate ,Leukemia, Myeloid, Acute ,Sample size determination ,030220 oncology & carcinogenesis ,Female ,business ,030215 immunology - Abstract
Much recent attention has been given to evaluating surrogate endpoints for overall survival (OS) in various cancers. Valid surrogate endpoints for OS can reduce sample size, reduce follow-up duration, and decrease costs for trials. The US Food and Drug Administration (FDA) has approved new drugs in
- Published
- 2016
8. Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG
- Author
-
Elihu H. Estey, Bob Löwenberg, Frederick R. Appelbaum, Harry P. Erba, Roland B. Walter, Megan Othus, Thomas Pabst, Gert J. Ossenkoppele, Marie Christiane Vekemans, Stephen H. Petersdorf, Hematology, and CCA - Innovative therapy
- Subjects
Oncology ,Clinical Trials as Topic ,medicine.medical_specialty ,business.industry ,Remission Induction ,Complete remission ,Myeloid leukemia ,Adult Acute Myeloid Leukemia ,Hematology ,Therapeutic resistance ,Clinical trial ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Refractory ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Relapsed refractory ,medicine ,Humans ,Online Only Articles ,business ,Intensive care medicine - Abstract
Despite incremental progress over the last several decades, adult acute myeloid leukemia (AML) remains difficult to treat, and many patients experience therapeutic resistance, i.e. never attain a complete remission (CR) despite living long enough to have done so (i.e. are “primary refractory”)
- Published
- 2015
9. Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG
- Author
-
Marie-Christianne Vekemans, Harry P. Erba, Thomas Pabst, Roland B. Walter, Frederick R. Appelbaum, Megan Othus, Stephen H. Petersdorf, Elihu H. Estey, Bob Löwenberg, and Gert J. Ossenkoppele
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Proportional hazards model ,medicine.medical_treatment ,Immunology ,Population ,Hazard ratio ,Induction chemotherapy ,Salvage therapy ,Cell Biology ,Hematology ,Biochemistry ,Surgery ,Clinical trial ,Internal medicine ,Cohort ,medicine ,business ,education ,Neoadjuvant therapy - Abstract
Background: Therapeutic resistance, i.e. the failure to achieve complete remission (CR) or relapse from CR, is common in adult acute myeloid leukemia (AML). It is well recognized that the likelihood of complete remission (CR) and survival after receipt of therapy for relapsed/refractory AML (Òsalvage therapyÓ) varies widely with prior response duration being the primary predictor of both outcomes. One approach to salvage therapy trials would permit inclusion regardless of prior CR duration (CRD) given the possibility that a new drug might only be effective with longer CRD and that even with longer CRD standard therapies are hardly satisfactory. A second, more common approach relies on CRD to create a ÒhomogenousÓ population to facilitate data interpretation; yet, various arbitrary CRD cut-points have been used. This work examines whether a particular CRD might be used based on the relation between CRD and subsequent survival. Methods: We used information on patients with newly diagnosed AML other than acute promyelocytic leukemia receiving curative-intent treatment on 5 trials conducted by the Dutch-Belgian Cooperative Trial Group for Hematology/Oncology and the Swiss Group for Clinical Cancer Research (HOVON/SAKK; n=1,306) or on the SWOG S0106 trial (n=586). Failure was considered as completion of induction therapy without CR (CRD=0) or as relapse from CR. Survival after failure (SAF) was measured from the date of completing protocol induction therapy without report of CR or from the date of relapse, with SAF measured until the date of death from any cause with patients last known to be alive censored at the date of last contact. SAF was estimated using the Kaplan-Meier method. Cox regression was used to analyze the association between SAF and CR duration; the latter was modeled both quantitatively and categorically. Regression analyses with all three cohorts were stratified by cohort. Results: Among the 1,892 patients, 1,026 (54%) patients (median age: 48 years [range: 15-77 years]) failed induction therapy (n=430) or had a first CR duration of 2 years or less (n=596) and were included in our analyses. In the total patient cohort as well as in both treatment sites, longer CR duration was associated with longer SAF. In the total patient cohort, there was no evidence that the SAF for patients with first CR duration of 6 months or less was different or better than the SAF for patients who were primary refractory to induction therapy (see table). The same conclusion could be drawn when analyzing patients treated on HOVON/SAKK trials as separate cohort. In the SWOG cohort, there was no evidence that SAF with patients with first CR duration of 9 months or less was different or better than SAF of patients who were refractory to induction therapy. Conclusions: Limitations of this work include incomplete information about whether primary induction failures received 1 or 2 induction courses before failure was declared and about the therapy received after failure, as well as the presence of inter-cohort heterogeneity. Nonetheless, assuming SAF is a crucial endpoint and using data to establish its relation with CRD, our study indicates that patients who are primary refractory to 1-2 courses of intensive induction chemotherapy or who relapse within 6 months have distinctly different SAF than patients who relapse after a CR duration of more than 6 months. Regardless of whether these 2 subsets are deemed equally eligible for trials, our data could form the basis for rational stratification of patients enrolled on a trial for relapsed/refractory AML. Table 1: Hazard ratio (95% confidence interval) for Cox regression models for survival after failure (SAF). HOVON/SAKK(n=685) SWOG(n=341) All Patients(n=1,026) Failed Induction (Reference) (Reference) (Reference) CR 0-3 months 0.92 (0.69-1.23) 1.70 (0.96-3.02) 1.08 (0.83-1.40) CR 3-6 months 1.05 (0.83-1.32) 1.67 (1.07-2.62) 1.20 (0.98-1.47) CR 6-9 months 0.64 (0.51-0.81) 1.25 (0.84-1.87) 0.77 (0.63-0.94) CR 9-12 months 0.43 (0.31-0.59) 0.88 (0.59-1.30) 0.56 (0.43-0.72) CR 1-2 years 0.39 (0.30-0.52) 0.55 (0.36-0.83) 0.45 (0.35-0.56) Disclosures Petersdorf: Author deceased: Author recently deceased Other.
- Published
- 2014
10. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.
- Author
-
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, and Stirewalt DL
- Subjects
- Acute Disease, Age Factors, Aged, Clinical Trials as Topic, Female, Genotype, Humans, Leukemia, Myeloid therapy, Male, Middle Aged, Multivariate Analysis, Nucleophosmin, Prognosis, Survival Analysis, Treatment Outcome, United Kingdom, United States, Leukemia, Myeloid genetics, Mutation, Nuclear Proteins genetics, Tandem Repeat Sequences genetics, fms-Like Tyrosine Kinase 3 genetics
- Abstract
Purpose: Younger patients with acute myeloid leukemia (AML) harboring NPM1 mutations without FLT3-internal tandem duplications (ITDs; NPM1-positive/FLT3-ITD-negative genotype) are classified as better risk; however, it remains uncertain whether this favorable classification can be applied to older patients with AML with this genotype. Therefore, we examined the impact of age on the prognostic significance of NPM1-positive/FLT3-ITD-negative status in older patients with AML., Patients and Methods: Patients with AML age ≥ 55 years treated with intensive chemotherapy as part of Southwest Oncology Group (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI/MRC) trials were evaluated. A comprehensive analysis first examined 156 patients treated in SWOG trials. Validation analyses then examined 1,258 patients treated in MRC/NCRI trials. Univariable and multivariable analyses were used to determine the impact of age on the prognostic significance of NPM1 mutations, FLT3-ITDs, and the NPM1-positive/FLT3-ITD-negative genotype., Results: Patients with AML age 55 to 65 years with NPM1-positive/FLT3-ITD-negative genotype treated in SWOG trials had a significantly improved 2-year overall survival (OS) as compared with those without this genotype (70% v 32%; P < .001). Moreover, patients age 55 to 65 years with NPM1-positive/FLT3-ITD-negative genotype had a significantly improved 2-year OS as compared with those age > 65 years with this genotype (70% v 27%; P < .001); any potential survival benefit of this genotype in patients age > 65 years was marginal (27% v 16%; P = .33). In multivariable analysis, NPM1-positive/FLT3-ITD-negative genotype remained independently associated with an improved OS in patients age 55 to 65 years (P = .002) but not in those age > 65 years (P = .82). These results were confirmed in validation analyses examining the NCRI/MRC patients., Conclusion: NPM1-positive/FLT3-ITD-negative genotype remains a relatively favorable prognostic factor for patients with AML age 55 to 65 years but not in those age > 65 years., (© 2015 by American Society of Clinical Oncology.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.